Market Size and Growth
The Transcatheter Aortic Valve Replacement (TAVR) Market size reached US$ 5.1 billion in 2025 and is expected to reach US$ 12.3 billion by 2033, growing with a CAGR of 11.5% during the forecast period 2026-2033.
As an alternative, the procedure segments an extra valve to replace the aortic valve. The valve replacement method necessitates open-heart surgery with a sternotomy, in which the chest is divided during the surgical process. TAVR operations, on the other hand, can be conducted with minimal incisions that leave all of the chest bones in situ.
Transcatheter Aortic Valve Replacement (TAVR) Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on the market segmentation.
It also provides global Transcatheter Aortic Valve Replacement (TAVR) Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Transcatheter Aortic Valve Replacement (TAVR) Market in the United States and Canada produces the utmost share. Whereas the European Transcatheter Aortic Valve Replacement (TAVR) Market is projected to continue its presence globally during the period of 2023-2030.
Market Scope
| Metrics | Details |
| Market CAGR | 12.3% |
| Segments Covered | By Product Type, By Surgical Procedure, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | Europe |
For More Insights Download Sample
Market Dynamics and Trends
The global transcatheter aortic valve replacement (TAVR) market is driven by several growth factors, such as the rising prevalence of cardiovascular disorders such as heart failure (HF), coronary artery diseases (CAD), and hypertension.
Increasing clinical trials for transcatheter aortic valve replacement (TAVR) products are expected to drive market growth.
In August 2022, Edwards Lifesciences conducted a study to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS). Moreover, JenaValve Technology, Inc., on May 22, 2020, conducted a study examining the use of TAVR (Transcatheter Aortic Valve Replacement), a minimally invasive procedure designed to replace the aortic valve inside the heart. TAVR will be performed using the JenaValve Pericardial TAVR System, which is intended to help treat symptomatic severe aortic regurgitation.
In addition, there have been significant engineering breakthroughs in designing THVs and the delivery system since the initial TAVR. The original SAPIEN valve required a 22–24 French (Fr) sheath, which has been reduced to 14–16 Fr for the SAPIEN 3 and 14 Fr for the Evolut Pro Plus. As a result, the number of vascular problems associated with the treatment has decreased dramatically, and the proportion of cases that can be performed with the transfemoral technique has increased.
For instance, valve design has been repeated consecutively over three generations of the balloon-expandable SAPIEN system (Edwards Lifesciences, CA, USA) and the self-expandable CoreValve-Evolut system (Medtronic, CA, USA) to improve hemodynamics and function. The height of the external polyethylene terephthalate (PET) skirt of the latest SAPIEN 3, the Ultra, has been increased by 40% to reduce PVL.
Furthermore, the mechanically-expandable Lotus Edge valve (Boston Scientific, Malborough, MA, USA), which is fully recapturable and repositionable with high radial strength, has been proposed to offer a theoretical advantage in very heavily calcified anatomy, but this is yet to be definitively demonstrated. Thus, from the above statements, the market is expected to drive in the forecast period.
Restraint
The high cost associated with the procedure, the lack of skilled professionals and stringent regulatory approval for transcatheter products are the factors that the market is expected to be hampered in the forecast period.
Transcatheter Aortic Valve Replacement (TAVR) Market Industry Analysis
The transcatheter aortic valve replacement (TAVR) market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis etc.
Market Segment Analysis
Transfemoral (TF) Implantation segment is expected to hold the largest market share in transcatheter aortic valve replacement (TAVR) market.
The transfemoral (TF) implantation segment accounted for the largest market share in 2021. The segment benefits because transfemoral implantation is a standardized and uniform process in which a prosthetic valve is implanted through the femoral blood vessel with a less invasive procedure and negligible anesthesia. The transfemoral implantation procedure is the most prevalent catheter-based treatment, accounting for more than 80% of all transcatheter valve replacement (TAVR) cases worldwide.
For instance, Boston Scientific Corporation's ACURATE Neo AS Aortic Bioprosthesis for implantation using the ACURATE neo AS TF transfemoral delivery system is used in patients with severe aortic stenosis. Therefore, it has increased the adoption of transfemoral (TF) implantation procedures. Thus, the market segment accounted for the largest market share in the forecast period.
Market Geographical Share
Europe region holds the largest market share in the global transcatheter aortic valve replacement (TAVR) market
In 2021, Europe, countries such as France, Germany, and Italy accounted for the highest revenue share in the global market. The rising aortic valve procedures, technological advancements in the devices, product launches, and approvals by the market players are the factors to drive the market in the forecast period. For instance, on August 28, 2022, a revolutionary artificial intelligence (AI) algorithm identified aortic stenosis patients at high risk of mortality who could benefit from treatment using routine echocardiograms. The groundbreaking research was presented today at the ESC Congress 2022 hotline session.
AI-ENHANCED AS examined whether an AI algorithm developed from echocardiographic parameters routinely used in clinical practice could identify moderate-to-severe and severe aortic stenosis phenotypes associated with increasing five-year mortality. Therefore, technological advancement in the devices has accounted for the largest market share in Europe, from the above factors.
Market Companies
Major key players in the transcatheter aortic valve replacement (TAVR) market are St. Jude Medical, Inc., Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, HLT, Inc., JenaValve Technology, Inc., Direct Flow medical, Inc., Meril Life Sciences Pvt. Ltd., Transcatheter Technologies GmbH, SYMETIS SA.
Medtronic Plc:
Overview:
Medtronic plc is an American-Irish registered medical device company primarily operating in the United States. It has an operational and executive headquarters in Fridley, Minnesota, in the US. Moreover, it develops and manufactures devices and therapies to treat more than 30 chronic diseases, including heart failure, Parkinson's disease, urinary incontinence, Down syndrome, obesity, chronic pain, spinal disorders, and diabetes. It is operated in 140 countries and employs over 104,950 people.
Product Portfolio:
Evolut R valve: The Medtronic Evolut R (EVR) is a novel transcatheter heart valve designed to allow precise implantation at the intended position and to minimize prosthesis dysfunction as well as procedural complications.
Key Developments
March 2026: The market continues to expand due to increasing adoption of minimally invasive cardiac procedures, supported by growing awareness, aging populations, and healthcare infrastructure improvements across regions like North America and Asia-Pacific.
February 2026: At the “Miami Valves 2026” conference, global experts showcased next-generation transcatheter technologies, advanced imaging tools, and upcoming valve devices expected to enter the market within the next few years, reflecting rapid technological innovation in TAVR.
February 2026: Edwards Lifesciences reported strong growth in its TAVR segment, driven by rising patient referrals and expectations of expanded clinical guidelines and reimbursement policies in 2026, indicating broader adoption of minimally invasive valve procedures.
January 2026: A major regulatory development occurred as the U.S. Federal Trade Commission blocked a proposed acquisition between Edwards Lifesciences and JenaValve, aiming to preserve competition in TAVR systems for treating aortic regurgitation. This highlights increasing regulatory scrutiny and the importance of innovation competition in the market.
The global transcatheter aortic valve replacement (TAVR) market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
